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The present study tracks the development of low-level azole resistance in in vitro fluconazole-adapted strains
of Candida albicans, which were obtained by serially passaging a fluconazole-susceptible dose-dependent strain,
YO1-16 (fluconazole MIC, 16 g ml1) in increasing concentrations of fluconazole, resulting in strains YO1-32
(fluconazole MIC, 32 g ml1) and YO1-64 (MIC, 64 g ml1). We show that acquired resistance to
fluconazole in this series of isolates is not a random process but is a gradually evolved complex phenomenon
that involves multiple changes, which included the overexpression of ABC transporter genes, e.g., CDR1 and
CDR2, and the azole target enzyme, ERG11. The sequential rise in fluconazole MICs in these isolates was also
accompanied by cross-resistance to other azoles and terbinafine. Interestingly, fluorescent polarization mea-
surements performed by using the fluorescent probe 1,6-diphenyl-1,3,5-hexatriene revealed that there was a
gradual increase in membrane fluidity of adapted strains. The increase in fluidity was reflected by observed
change in membrane order, which was considerably decreased (decrease in fluorescence polarization values, P
value) in the adapted strain (P value of 0.1 in YO1-64, compared to 0.19 in the YO1-16 strain). The phospho-
lipid composition of the adapted strain was not significantly altered; however, ergosterol content was reduced
in YO1-64 from that in the YO1-16 strain. The asymmetrical distribution of phosphatidylethanolamine (PE)
between two monolayers of plasma membrane was also changed, with PE becoming more exposed to the outer
monolayer in the YO1-64 strain. The results of the present study suggest for the first time that changes in the
status of membrane lipid phase and asymmetry could contribute to azole resistance in C. albicans.
Candida albicans is most frequently associated with human
fungal infections. Widespread and prolonged usage of azoles in
recent years has led to the rapid development of drug resis-
tance in C. albicans, which has posed serious problems for its
successful use in chemotherapy. C. albicans cells acquire mul-
tidrug resistance (MDR) during the course of a treatment;
wherein continued exposure to drug(s) results in the develop-
ment of multiple resistance mechanism(s) which include alter-
ations of the target enzyme (lanosterol 14- demethylase or
ERG11), overexpression of drug extrusion pumps belonging to
either the major facilitators or the ATP-binding cassette
(ABC) superfamily (23, 35). There is evidence to suggest that
impaired import of an antifungal agent which may involve
membrane alterations through changes in the sterol and/or
lipid content or formation of a biofilm may also be an impor-
tant attribute of azole resistance (14, 23). In this context the
importance of the membrane lipid phase (fluidity) in the over-
all scenario of MDR has only recently been appreciated. Hu-
man MDR1 (P-glycoprotein) activity has been found to be
sensitive to the nature and the physical state of the lipid matrix
(12). The intimate association of both P-glycoprotein (P-gp)
and its hydrophobic substrates with the membrane matrix do
suggest a possible role of membrane lipids in the modulation of
drug binding activity of P-gp (30, 31, 33). It is observed that
membrane cholesterol directly interacts with P-gp and affects
drug binding to the membrane bilayer, which in turn could
affect drug availability to P-gp (34). We have earlier demon-
strated that CDR1 (ABC transporter of C. albicans)-mediated
drug resistance was susceptible to changes in membrane fluid-
ity (32). Interestingly, the physical state of membrane has also
been shown to affect gene expression and signal transduction in
yeast (25, 29).
The fact that most azole-resistant isolates are known to be
associated with clinical failure justifies the need for a detailed
analysis of the mechanisms of resistance in such isolates. The
clonal nature of C. albicans makes it imperative that a matched
set of susceptible and resistant isolates derived from a single
strain be examined in characterizing the molecular mecha-
nisms of resistance. The emergence of drug resistance in serial
isolates of C. albicans from patients undergoing azole treat-
ment in most cases was shown to develop from a previously
more susceptible strain and was associated with the overex-
pression of certain MDR genes, such as CDR1, CDR2,
CaMDR1, and ERG11 (35). There are also instances where
overexpression of known MDR genes is not directly correlated
with azole resistance, implying the contribution of yet other
unknown mechanisms of resistance. It appears that azole re-
sistance in C. albicans is a multifactorial phenomenon.
Although in vivo studies provide invaluable clues to the
molecular changes associated with azole resistance, it is diffi-
cult to determine the time point when molecular changes result
in a resistant phenotype. In several instances a mixed popula-
tion of isolates is obtained (21). To overcome such problems,
several groups have developed in vitro systems for the devel-
opment of azole resistance by exposing C. albicans cells to
increasing concentrations of fluconazole (1, 8). The present
study was undertaken to delineate the cellular changes that
may accompany the development of azole resistance in se-
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quentially adapted in vitro fluconazole-resistant strains. The
adaptation to fluconazole led to the overexpression of drug
extrusion pump-encoding genes, particularly CDR1 and CDR2
and the gene for the azole target enzyme, ERG11. Of note was
an increase in membrane fluidity, as was evident by fluores-
cence polarization measurements. Since the phospholipid
composition of the adapted strain was not altered, the ob-
served fluctuation in ergosterol content appeared to be respon-
sible for the change in membrane order. The observed changes
in membrane fluidity were also associated with the change in
membrane lipid asymmetry of adapted strains. Our results
suggest that membrane alterations associated with fluconazole
resistance should be an important consideration in delineating
the complex mechanism of drug resistance in C. albicans cells.
MATERIALS AND METHODS
Isolation of fluconazole-resistant yeast strains. C. albicans strain YO1-16 used
in this study is a clinical isolate which was a kind gift from NDDR, Ranbaxy,
India. The MIC of this strain (YO1-16) was found to be 16 g ml1, and hence
it is a susceptible dose-dependent (SDD) strain, as per NCCLS guidelines.
Fluconazole-resistant mutants of this strain were obtained by serial passage (5 to
10 passages, each of 48-h duration) in increasing concentrations of fluconazole
(2 MIC) from 32 to 64 g ml1 in RPMI media, resulting in sequentially
adapted strains, YO1-32 and YO1-64, with MICs of 32 and 64 g ml1, respec-
tively. MICs of the strains were determined using a broth microdilution method
(11) and reading of the endpoints at 48 h. Cells were added to the microtiter
plate at a final cell density of 2.5  103 cells ml1. The MIC test end point was
defined as the lowest drug concentration that gave 80% inhibition of growth
compared with drug-free controls (MIC80). For all experimental studies the yeast
cells were maintained on yeast extract-peptone-dextrose (YEPD) medium at
37°C.
Fluorescence polarization and sterol analysis. Fluidity measurements were
carried out as described earlier (2) by using the fluorescent probe 1,6-diphenyl-
1,3,5-hexatriene (DPH) as a reporter. Briefly, cells were incubated with Zymol-
yase (100 U/g wet weight) at 37°C for 3 h with gentle shaking to remove the cell
wall. Spheroplast preparation was monitored turbidometrically by checking the
ability of 0.2% sodium dodecyl sulfate to lyse the enzyme-digested cells. Fluo-
rescence polarization was measured at excitation and emission wavelengths of
360 and 426 nm, respectively. The measured fluorescence intensities were cor-
rected for background fluorescence and the light scattering from the unlabeled
sample. Sterols were extracted (2) and quantified as described previously by
Arthington-Skaggs et al. (3).
Membrane lipid asymmetry measurements. Fluorescamine, which specifically
labels exposed aminophospholipids (9), was used for labeling of C. albicans
resistant and susceptible strains. The protocol of labeling and quantitative esti-
mation of asymmetry was strictly followed as described previously (10). Briefly,
cells were harvested in mid-log phase by centrifuging at 3,000 rpm (Beckman
model TJ-6) for 5 min at 4°C and washed two to three times with buffer A (100
mM potassium phosphate–5 mM EDTA, pH 7.5). The harvested cells (0.6 g wet
weight) were resuspended in 5 ml of buffer B (100 mM potassium phosphate and
600 mM KCl, pH 8.2) and kept at 4°C with gentle swirling. Fluorescamine (15.6
mM) in dehydrated dimethyl sulfoxide was added dropwise to the cell suspension
with constant gentle swirling. After 30 s the reaction was stopped by adding an
equal volume of 1 M ammonia in 600 mM KCl. The cells were centrifuged and
washed at 4°C three to four times till the color of the dye disappeared from the
supernatant. Resolved phospholipids and derivatized phosphatidylethanolamine
(PE) were scraped off from thin-layer chromatography (TLC) plates, and their
phosphate content was estimated (17).
Analysis of mRNA in C. albicans adapted strains. Total RNA isolation from C.
albicans cells was done as described earlier (19). Northern analysis and transfers
were done using standard laboratory protocols. RNA was isolated from strains
grown in YEPD media in the absence of any antifungal drug. A 1.8-kb EcoRV
fragment of CaMDR1 and DNA probes specific for CDR1 and CDR2 (PCR
amplified from C. albicans ATCC 10261 genomic DNA as described previously
[19]) were used as molecular probes for Northern analysis. Oligonucleotides
(forward, 5 TTCTAGAAGATCATAACTCA 3, and reverse, 5 GTTAATCG
ATCTAAGTAACA 3) were used to amplify ERG11. The probes were partially
sequenced to confirm their identities.
Glucose-induced rhodamine 6G (R6G) efflux. Efflux of R6G was determined
essentially using a protocol described by Maesaki et al. (22). Briefly, yeast cells
were grown overnight in YEPD media. Cells (108) were transferred to 100 ml of
fresh YEPD media and allowed to grow for 4 h; they were then resuspended in
phosphate-buffered saline buffer at a cell density of 108 cells ml1 and incubated
at 37°C for 1 h in a shaker. R6G was then added at a final concentration of 10
M and incubated for 25 min (till the dye showed a steady intracellular level of
accumulation). One mole of glucose was then added to initiate R6G efflux.
Samples of 1 ml in volume were withdrawn at the indicated time points and
centrifuged at 9,000  g for 2 min. The resulting supernatant was collected, and
absorption was measured at 527 nm. Glucose-free controls were included in all
experiments.
RESULTS AND DISCUSSION
Characterization of fluconazole-resistant strains. The C. al-
bicans strains YO1-32 and YO1-64 were isolated by serial
passage of a fluconazole-susceptible-dose-dependent clinical
isolate, YO1-16, through medium containing fluconazole (see
Materials and Methods). This was done to enhance the MIC
threshold value for the YO1-16 strain to levels of 64 g ml1,
which are generally considered acceptable values of clinical
drug resistance in C. albicans (28). The adapted strain exhib-
ited a twofold increase in the MIC of fluconazole that was
determined by standard methods of antifungal susceptibility
testing. The fluconazole resistance phenotype in the adapted
strains (YO1-32 and YO1-64) was stable even after 10 to 20
transfers in drug-free media. In order to ensure stability of in
vitro resistance, fluconazole susceptibility was routinely
checked at each subsequent passage in drug-free media. The
isogenicity of adapted strains was confirmed by using the
CARE-2 fingerprinting probe (20) (Fig. 1a). The adapted
strains (YO1-32 and YO1-64) showed no significant differ-
ences in growth compared with the progenitor strain, YO1-16
(Fig. 1b).
Susceptibilities of in vitro-adapted C. albicans strains to
other drugs. Earlier reports have shown that fluconazole-re-
sistant clinical isolates are frequently cross-resistant to other
azoles and can also be cross-resistant to polyenes (35). We
therefore examined if adaptation to fluconazole was also asso-
ciated with cross-resistance to other antifungals. Both spot
assays and NCCLS microdilution method were employed for
testing resistance to drugs such as azoles and allylamine (Fig. 2
and Table 1). Strains YO1-64 and YO1-32 were found to be
more resistant to both ketoconazole and itraconazole than the
progenitor cell. Besides azole drugs, the YO1-64 strain also
exhibited significant resistance to terbinafine, an allylamine
which inhibits the ERG1 gene product in the ergosterol bio-
synthetic pathway. Notably, although the differences in MICs
obtained for different antifungals were small, they were con-
sistently observed by repeated testing of isolates, which was
also corroborated by spot assays. Thus, in spite of the fact that
the adapted strains exhibited low levels of resistance to azoles
(only fourfold-higher MICs for fluconazole), this difference in
susceptibilities appeared to be sufficient to result in the devel-
opment of the MDR phenotype exhibited by these cells.
Adapted strains exhibit elevated levels of membrane fluid-
ity. Since the intracellular drug level is dependent not only on
active drug efflux but also on the rate of its drug import (35),
the status of the membrane lipid matrix could be an important
determinant in the development of drug resistance. In the
following experiments this aspect was examined. Spectral anal-
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ysis and subsequent quantification of extracted sterols (3) re-
vealed that the YO1-16 and YO1-32 strains have similar levels
of ergosterol. However, the ergosterol content was found to be
reduced in strain YO1-64 strain (see Table 2). In many in-
stances reduced ergosterol content is associated with increased
resistance to polyenes like nystatin (16), which exerts it anti-
fungal effect by binding to the membrane ergosterol. However,
our results show that the adapted strains remained susceptible
to nystatin (Table 1; Fig. 2). This is not unusual, since prior
studies by members of our group and others have shown that
binding of polyenes to membranes is not solely dependent
upon sterols, since other membrane components and factors,
such as fatty acids and phospholipids, could contribute to their
action (5, 24).
The membrane order (fluidity) of the adapted strain was
determined by using the fluorescent probe DPH. Interestingly,
fluorescence polarization measurements of the adapted strain
YO1-64 showed enhanced fluidity (low P value) compared to
its susceptible counterpart, in the following order: YO1-64 had
greater fluidity than YO1-32, which had greater fluidity than
YO1-16 (Fig. 3a). The phospholipid composition of the
adapted cells did not contribute to observed change in fluidity,
since it was not significantly altered between resistant and
susceptible strains except for sphingolipid content, which was
higher in resistant strains than in susceptible isolates (15) (Ta-
ble 2). Of note, the observed enhanced fluidity of the YO1-64
strain was probably associated with decreased levels of ergos-
terol. The decreased level of ergosterol in the YO1-64 strain
could also reflect a decrease in the activity of 5,6desaturase
enzyme, which is suppressed when 14-demethylase (target
enzyme of fluconazole) activity is reduced either pharmacolog-
ically (by azoles) or genetically (by gene disruption) (26, 35).
Whether desaturation of fatty acids or intermediates of the
ergosterol biosynthetic pathway may also contribute to ob-
served elevated levels of membrane fluidity remains to be
analyzed.
Adapted strain shows change in membrane phospholipid
asymmetry. We have earlier demonstrated that the membrane
phospholipid translocation between the two monolayers of the
lipid bilayer of the plasma membrane of C. albicans is main-
tained by an energy-dependent process mediated by the ABC
transporter protein, e.g., Cdr1p (10). Keeping in view that
Cdr1p functioning is also sensitive to alterations in membrane
fluidity (32), we examined whether adapted resistant strains
will display any change with regard to asymmetrical distribu-
tion of phospholipids. The fluorescent dye fluorescamine,
which labels exposed aminophospholipids, was used to quan-
titate aminophospholipids. Since phosphatidylserine is local-
ized predominantly in the cytoplasmic leaflet of the lipid bi-
layer, the dye could label only PE, which is also present in the
outer monolayer (10). The labeling experiments revealed that
the percentage of exposed PE was highest in the YO1-64 strain
(Fig. 3b), which also showed maximum expression of CDR1
(discussed below). No statistically significant increase in per-
centage labeling of PE was, however, observed in strain YO1-
32, which also showed low-level expression of CDR genes.
Interestingly, the membranes of strain YO1-64 were more
fluid, which may be an important factor regulating phospho-
lipid translocation mediated by overexpressed CDR1. The in-
volvement of Cdr1p in phospholipid translocation was earlier
demonstrated from the fact that an increased amount of PE in
the outer leaflet of the plasma membrane of the mycelial form
correlates well with CDR1 expression, which is also more pro-
nounced in mycelia than in the bud form of C. albicans (10). Of
note, the exposed PE was also found to be decreased in a
CDR1 disruptant strain. Thus, there appears to be a causal
relationship between CDR1 overexpression and phospholipid
translocation.
Molecular changes accompanying azole resistance. As men-
tioned, in many instances overexpression of genes like CDR1/2
and CaMDR1 in clinical isolates of C. albicans have been as-
sociated with fluconazole resistance (19, 35). We compared the
expression levels of potential MDR genes of C. albicans, such
as those for CDR1, CDR2, CaMDR1, and the azole target
enzyme, ERG11, in these strains. The SDD strain YO1-16 did
not show any detectable levels of CDR1 or CDR2 mRNA (Fig.
4). In contrast, a two-step induction of CDR1 and CDR2 genes
was observed which was highest in the azole-resistant strain,
YO1-64 (Fig. 4). While the YO1-16 strain showed very low
FIG. 1. Isogenicity and growth patterns of fluconazole-susceptible
and -resistant C. albicans strains. (a) CARE-2 hybridization pattern of
EcoRI-digested chromosomal DNA of the C. albicans adapted strains.
The positions of the molecular size markers (in kilobases) are shown
on the left-hand side of the figure. (b) Comparison of growth curve of
the fluconazole-susceptible and -resistant strains: the cells were grown
in YEPD media at 37°C. Aliquot of cells was taken every 2 h till 22 h,
and the optical density was measured at A600.
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levels of ERG11, both YO1-32 and YO1-64, for which MICs
are higher, showed up-regulation of ERG11. There was no
significant difference in CaMDR1 expression between these
isolates. It should be pointed out that while the expression of
ERG11 is detected in most of the susceptible isolates, the SDD
strain YO1-16 used in this study showed only low levels of
ERG11 transcript. This is not unusual, since earlier studies
have included similar observations (13, 21).
Overexpression of CDR1/2 genes in clinical isolates of C.
albicans is known to render a cell resistant to many different
azoles, while overexpression of CaMDR1 appears to be specific
for fluconazole resistance and is not associated with resistance
to other azoles (35). Therefore, the cross-resistance to azoles
of adapted C. albicans cells would suggest that it could be
predominantly due to their decreased accumulation of drug
mediated by overexpressed efflux pumps, such as Cdr1p and
Cdr2p (Fig. 2). We checked the efflux of R6G, a well-known
fluorescent compound that is transported by a wide variety of
MDR proteins (6, 7). In most of the studies, the net intracel-
lular accumulation of the drug is taken as an indirect criterion
of efflux measurements, but such measurements do not exclude
the contribution of drug import by diffusion. Therefore, in
order to minimize the contribution of drug import, we used
R6G and studied its efflux in energy-starved cells. Figure 5
depicts a rapid drop of R6G fluorescence in the supernatant,
which became steady after 25 min. The decrease in R6G flu-
orescence in the supernatant of energy-starved cells was due to
its rapid diffusion into the cells. When the efflux was initiated
by energy supplementation (addition of glucose), there was a
steady increase in R6G fluorescence in the supernatant, which
FIG. 2. Susceptibilities of adapted strains to antifungal agents. The yeast cells were grown overnight on YEPD plates at 37°C. Cells were then
suspended in normal saline to an optical density of 0.1 (A600). Five microliters of fivefold serial dilutions of each yeast culture were spotted onto
YEPD plates in the absence (control) and presence of the indicated drugs: fluconazole (8 g ml1), ketoconazole (0.16 g ml1), itraconazole
(0.16 g ml1), terbinafine (12.5 g ml1), and nystatin (1 g ml1). Growth differences were recorded following incubation of the plates for 48 h
at 37°C. Growth was not affected by the presence of the solvents used for the drugs.
TABLE 1. Azole susceptibility of adapted C. albicans strainsa
Strain
MICb (g ml1) of:
Source
FLC ITRA KETO TERB NYS
YO1–16 16 0.125 0.03125 0.5 5 NDDR, Ranbaxy
India
YO1–32 32 0.25 0.0625 1 5 This study
YO1–64 64 0.25 0.0625 2 5 This study
a MICs were determined by a microdilution method and by reading end points
after a 48-h incubation of plates at 37°C as described in Materials and Methods.
FLC, fluconazole; ITRA, itraconazole; KETO, ketoconazole; TERB, terbin-
afine; NYS, nystatin.
b MIC test end point was defined as the lowest drug concentration that gave
80% inhibition of growth.
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was due to its efflux from the cells mediated by drug extrusion
pumps like CDR1 and CDR2. As can be seen in Fig. 5, the
adapted strain could elicit an increased glucose-induced drug
efflux that was more pronounced in YO1-64 than in the parent
strain. However, this difference became more apparent at later
time points of glucose supplementation, when the difference in
the percentage efflux of R6G in YO1-64 was almost twofold
compared to YO1-16 strain (Fig. 5, inset). It should be pointed
out that at early time points all the strains had similar levels of
R6G efflux. Of note, no R6G efflux was observed when these
strains were maintained in the absence of glucose. Thus, the
observed enhanced energy-dependent R6G efflux in YO1-64
compared to YO1-32 strains probably contributes to resis-
tance.
Taken together, our results demonstrate that in vitro drug
resistance exhibited by a fluconazole-adapted series of isolates
correlates well with that observed in vivo in a clinical situation
wherein a stepwise increase in acquisition of MDR traits is
observed. Interestingly, the gradual onset of resistance mech-
anisms in the sequentially fluconazole-adapted isolates of C.
albicans is associated with changes in membrane lipid fluidity
and asymmetry. That the fluctuation in lipid environment
could also affect drug susceptibilities is apparent from several
studies wherein both the import and export of drugs are shown
to be affected by membrane perturbations (12, 18, 27, 32).
Recent results from our laboratory show that azole-resistant
clinical isolates of C. albicans possess altered membrane fluid-
ity (Prasad et al., unpublished observations). Of interest, resis-
FIG. 3. (a) Fluorescence polarization measurements in flucon-
azole-susceptible and -resistant strains. Fluorescence polarization
measurements were carried out using fluorescent probe DPH, as de-
scribed in Materials and Methods, at excitation and emission wave-
lengths of 360 and 426 nm, respectively. Each experiment was done in
triplicate, and the values represent means 	 standard deviations. (b)
Percentage labeling of phosphatidylethanolamine (PE) in plasma
membrane of C. albicans cells with fluorescamine. Cells were labeled
with fluorescamine as described in Materials and Methods. After la-
beling, cells were washed and lipids were extracted. The percentage of
derivatized PE was determined as described in Materials and Methods.
The results shown are the means of more than six independent exper-
iments 	 standard deviations.
FIG. 4. Northern blots of total RNA from fluconazole-susceptible
and -resistant C. albicans strains. RNA was isolated from cells grown
logarithmically and hybridized with probes specific for CDR1, CDR2,
MDR1, and ERG11. Hybridizations were performed as described in
Materials and Methods. The bottom panel shows the corresponding
gel load (25S rRNA).
TABLE 2. Phospholipid and sterol composition of fluconazole-susceptible and -resistant strains
Strain
Phospholipid content (%) (mean 	 SD)a
ERGb
SPH PI PS PC PE CL PA
YO1–16 1.30 	 1.14 13.73 	 5.35 14.52 	 0.44 45.67 	 4.32 16.07 	 3.25 5.80 	 0.72 2.11 	 0.78 1.2 	 0.06
YO1–32 2.33 	 0.49 12.87 	 3.03 13.13 	 2.14 44.21 	 4.50 15.54 	 1.77 8.59 	 1.89 2.48 	 1.41 1.26 	 0.05
YO1–64 4.38 	 1.24 13.5 	 1.42 12.32 	 2.02 40.75 	 6.78 17.93 	 2.07 8.93 	 2.25 1.95 	 0.48 0.74 	 0.06
a Phospholipid content of fluconazole-susceptible and -resistant C. albicans cells is expressed as a percentage of total lipids. Values represent means from at least
six determinations. Constituent phospholipids have been abbreviated as follows: SPH, sphingolipid; PI, phosphatidylinositol; PS, phosphatidylserine; PC, phosphati-
dylcholine; PE, phosphatidylethanolamine; CL, cardiolipin; PA, phosphatidic acid.
b Mean ergosterol content (ERG) of the cells is expressed as a percentage of the wet weight of the cell 	 the standard deviations of the mean of three sets of
experiments (3).
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tance to platelet microbicidal proteins by Staphylococcus au-
reus was also shown to be associated with variation in
membrane fluidity due to elevated levels of unsaturated mem-
brane lipids (4). In view of the accumulating evidence, it is
apparent that the changes in the membrane lipid environment
are associated with drug resistance, and therefore, the inter-
play between the physical state of membrane lipids and azole
resistance mechanisms in C. albicans probably requires a closer
look.
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